UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3025% above fair value
$591.17−2.14 (-0.36%)
Close on Nov 13, 2026Market cap $25.36BP/E 22.3Yield –
United Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
United Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was $1.42B, down 10.1% year over year. For fiscal 2025 it was $1.58B, up 8.9% from the year before. Over ten years it grew 8.0% a year on average. The highest annual figure on record is $1.58B in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.58B | +8.9% |
| FY2024 | Dec 31, 2024 | $1.45B | +17.1% |
| FY2023 | Dec 31, 2023 | $1.24B | +20.1% |
| FY2022 | Dec 31, 2022 | $1.03B | +70.2% |
| FY2021 | Dec 31, 2021 | $605.80M | -5.9% |
| FY2020 | Dec 31, 2020 | $643.50M | – |
| FY2019 | Dec 31, 2019 | -$141.70M | -116.8% |
| FY2018 | Dec 31, 2018 | $841.30M | -0.5% |
| FY2017 | Dec 31, 2017 | $845.90M | -22.6% |
| FY2016 | Dec 31, 2016 | $1.09B | +49.4% |
| FY2015 | Dec 31, 2015 | $731.90M | +28.2% |
| FY2014 | Dec 31, 2014 | $571.00M | +76.4% |
| FY2013 | Dec 31, 2013 | $323.76M | -27.9% |
| FY2012 | Dec 31, 2012 | $448.79M | +32.7% |
| FY2011 | Dec 31, 2011 | $338.32M | +78.8% |
| FY2010 | Dec 31, 2010 | $189.23M | +409.4% |
| FY2009 | Dec 31, 2009 | $37.15M | – |
| FY2008 | Dec 31, 2008 | -$77.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $334.20M | -18.6% |
| Q2 FY2026 | Jun 30, 2026 | $355.00M | -7.9% |
| Q1 FY2026 | Mar 31, 2026 | $348.40M | -13.5% |
| Q4 FY2025 | Dec 31, 2025 | $379.50M | +0.6% |
| Q3 FY2025 | Sep 30, 2025 | $410.40M | +13.3% |
| Q2 FY2025 | Jun 30, 2025 | $385.60M | +13.9% |
| Q1 FY2025 | Mar 31, 2025 | $402.60M | +8.4% |
| Q4 FY2024 | Dec 31, 2024 | $377.40M | +37.8% |
| Q3 FY2024 | Sep 30, 2024 | $362.20M | +6.4% |
| Q2 FY2024 | Jun 30, 2024 | $338.60M | +3.8% |
| Q1 FY2024 | Mar 31, 2024 | $371.30M | +24.7% |
| Q4 FY2023 | Dec 31, 2023 | $273.80M | +45.0% |
| Q3 FY2023 | Sep 30, 2023 | $340.30M | +4.0% |
| Q2 FY2023 | Jun 30, 2023 | $326.30M | +52.1% |
| Q1 FY2023 | Mar 31, 2023 | $297.70M | -0.9% |
| Q4 FY2022 | Dec 31, 2022 | $188.80M | +3.5% |
| Q3 FY2022 | Sep 30, 2022 | $327.20M | +35.7% |
| Q2 FY2022 | Jun 30, 2022 | $214.50M | -8.6% |
| Q1 FY2022 | Mar 31, 2022 | $300.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $182.40M | +132.7% |
| Q3 FY2021 | Sep 30, 2021 | $241.10M | +3.5% |
| Q2 FY2021 | Jun 30, 2021 | $234.60M | +53.2% |
| Q1 FY2021 | Mar 31, 2021 | -$52.30M | -129.2% |
| Q4 FY2020 | Dec 31, 2020 | $78.40M | +3.2% |
| Q3 FY2020 | Sep 30, 2020 | $232.90M | +18.8% |
| Q2 FY2020 | Jun 30, 2020 | $153.10M | -34.0% |
| Q1 FY2020 | Mar 31, 2020 | $179.10M | – |
| Q4 FY2019 | Dec 31, 2019 | $76.00M | -46.5% |
| Q3 FY2019 | Sep 30, 2019 | $196.10M | +23.3% |
| Q2 FY2019 | Jun 30, 2019 | $231.80M | +2.8% |
| Q1 FY2019 | Mar 31, 2019 | -$645.60M | -305.1% |
| Q4 FY2018 | Dec 31, 2018 | $142.00M | -3.2% |
| Q3 FY2018 | Sep 30, 2018 | $159.00M | -52.0% |
| Q2 FY2018 | Jun 30, 2018 | $225.50M | +134.4% |
| Q1 FY2018 | Mar 31, 2018 | $314.80M | +15.9% |
| Q4 FY2017 | Dec 31, 2017 | $146.70M | -19.4% |
| Q3 FY2017 | Sep 30, 2017 | $331.50M | – |
| Q2 FY2017 | Jun 30, 2017 | $96.20M | – |
| Q1 FY2017 | Mar 31, 2017 | $271.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $182.00M | – |
See a number that looks wrong?